We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Recently, Amplia Therapeutics Limited announced its FAK inhibitor AMP945 under research combined with FOLFIRINOX was effective on the preclinical model of pancreatic cancer.